You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GPRC5D

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)

Recruiting
  • Relapse/Refractory Multiple Myeloma
  • DeepTag-GPRC5D Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Oct 10, 2023

Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial (CAR-T (CAR-GPRC5D))

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Plasma Cell Leukemia
  • CAR-T (CAR-GPRC5D)
  • (no location specified)
Feb 26, 2023

Multiple Myeloma Trial in Wuhan (Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells)

Recruiting
  • Multiple Myeloma
  • Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 11, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Anti-GPRC5D CAR-T Cells Injection)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Anti-GPRC5D CAR-T Cells Injection
  • (no location specified)
Feb 18, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Kunming (Anti-GPRC5D CAR-T cells infusion)

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Anti-GPRC5D CAR-T cells infusion
  • Kunming, Yunnan, China
  • +1 more
Feb 21, 2023

Multiple Myeloma Trial in Xuzhou (anti-BCMA/GPRC5D CAR-T CELL)

Recruiting
  • Multiple Myeloma
  • anti-BCMA/GPRC5D CAR-T CELL
  • Xuzhou, Jiangsu, China
    Kailin Xu
Aug 19, 2022

Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial in Wuhan (CAR-T (CAR-GPRC5D))

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Plasma Cell Leukemia
  • CAR-T (CAR-GPRC5D)
  • Wuhan, Hu Bei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
May 17, 2022

Multiple Myeloma Trial in Hangzhou (GPRC5D-CAR-T)

Recruiting
  • Multiple Myeloma
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 12, 2022

Multiple Myeloma Trial (BMCA and GPRC5D dual target CAR-T cells(OriC321))

Not yet recruiting
  • Multiple Myeloma
  • BMCA and GPRC5D dual target CAR-T cells(OriC321)
  • (no location specified)
Apr 5, 2022

Multiple Myeloma in Relapse Trial in Shenzhen (BCMA/GPRC5D double CAR-T)

Recruiting
  • Multiple Myeloma in Relapse
  • BCMA/GPRC5D double CAR-T
  • Shenzhen, Guangdong, China
    Shenzhen Qianhai Shekou Free Trade Zone Hospital
Sep 28, 2023

Relapsed or Refractory Multiple Myeloma Trial in Tianjin (QLS32015)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jun 24, 2023

Multiple Myeloma Trial in New York (Infusion of MCARH109 T cells)

Active, not recruiting
  • Multiple Myeloma
  • Infusion of MCARH109 T cells
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 5, 2022

Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in New York (MCARH125, MCARH109)

Recruiting
  • Multiple Myeloma
  • +2 more
  • MCARH125
  • MCARH109
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jun 20, 2022

Multiple Myeloma Trial in Japan (Talquetamab)

Recruiting
  • Multiple Myeloma
  • Kamakura-shi, Japan
  • +5 more
Aug 11, 2022

Hematological Malignancies Trial in Worldwide (Talquetamab)

Recruiting
  • Hematological Malignancies
  • Birmingham, Alabama
  • +14 more
Jul 14, 2022

Hematological Malignancies Trial in Worldwide (Talquetamab)

Recruiting
  • Hematological Malignancies
  • Birmingham, Alabama
  • +82 more
Aug 11, 2022

Multiple Myeloma Trial in Boston (BMS-986393, Alnuctamab, Mezigdomide)

Not yet recruiting
  • Multiple Myeloma
  • Boston, Massachusetts
  • +1 more
Nov 2, 2023

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023

Relapsed or Refractory Multiple Myeloma Trial (Talquetamab)

Available
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Mar 6, 2023

Efficacy and Safety of Pacitol Inj.

Recruiting
  • Chronic Kidney Disease 5D
  • Secondary Hyperparathyroidism
    • Goyang-si, Gyeonggi-do, Korea, Republic of
      DongGuk university Ilsan hospital
    Nov 6, 2023

    Prostate Cancer, PET/CT Trial in Hefei ([68Ga]Ga-PSMA-D5, [68Ga]Ga-PSMA-11)

    Recruiting
    • Prostate Cancer
    • PET/CT
    • Hefei, Anhui, China
      The First Affiliated Hospital of China University of Science and
    Jul 19, 2023

    Hypertension and Dyslipidemia Trial in Seoul (CKD-348(5), CKD-828, D097, D337)

    Not yet recruiting
    • Hypertension and Dyslipidemia
    • Seoul, Korea, Republic of
      H plus Yangji hospital
    Feb 20, 2023

    Hypertension and Dyslipidemia Trial in Seoul (CKD-386(5), D013, D326, D337)

    Not yet recruiting
    • Hypertension and Dyslipidemia
    • Seoul, Korea, Republic of
      H plus Yangji hospital
    Jan 16, 2023

    EBV-associated Lymphomas Trial ((Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell

    Not yet recruiting
    • EBV-associated Lymphomas
    • (Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell line lysate
    • (no location specified)
    May 31, 2023

    Acute Myeloid Leukemia Trial in Houston (Azacitidine, Cladribine, Cytarabine)

    Recruiting
    • Acute Myeloid Leukemia
    • Houston, Texas
      M D Anderson Cancer Center
    Nov 17, 2022